Private Equity Portfolio News: Arbor Biotechnologies Closes $215 Million Oversubscribed Series B Financing to Advance Next-Generation Precision Editing Therapeutics
The most extensive toolbox of proprietary genomic editors in the industry to enable development of curative, next-generation genetic medicines Co-founded by David Walt, Ph.D. and Feng Zhang, Ph.D. CAMBRIDGE, Massachusetts…